All In Biotech

Drug Trial Radar · NCT02217709

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Phase 2 Trial of Phenelzine in Non-metastatic Recurrent Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Sep 8, 2014

Primary completion

Jun 29, 2020

Study completion Jun 29, 2020

Sponsor

Lead sponsor
University of Southern CaliforniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.

Conditions

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer
  • Stage I Prostate Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer
  • Stage III Prostate Cancer

Interventions

  • phenelzine sulfateDrug

    Given by mouth

  • laboratory biomarker analysisOther

    Correlative studies

  • questionnaire administrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With PSA Decline of >= 50% From Baseline Following at Least 12 Weeks of Treatment With Phenelzine SulfateTime frame: Baseline to up to 12 months
  2. Number of Patients With PSA Decline of >= 30% From Baseline Following at Least 12 Weeks of Treatment With Phenelzine SulfateTime frame: Baseline to up to 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Westside Cancer Center

    Beverly Hills, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Keck Medical Center of USC Pasadena

    Pasadena, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.